Literature DB >> 7559402

Cloning of a fibroblast growth factor receptor 1 splice variant from Xenopus embryos that lacks a protein kinase C site important for the regulation of receptor activity.

L L Gillespie1, G Chen, G D Paterno.   

Abstract

A cDNA clone, predicted to encode a variant form of the type 1 fibroblast growth factor receptor (FGFR1) containing a dipeptide Val-Thr (VT) deletion at amino acid positions 423 and 424 located within the juxtamembrane region, was isolated from a Xenopus embryo (stage 8 blastula) library. Sequence analysis of genomic DNA encoding a portion of the FGFR1 juxtamembrane region demonstrated that this variant form arises from use of an alternative 5' splice donor site. RNase protection analysis revealed that both VT- and VT+ forms of the FGFR1 were expressed throughout embryonic development, the VT+ being the major form. Amino acid position 424 is located within a consensus sequence for phosphorylation by a number of Ser/Thr kinases. We demonstrate that a VT+ peptide was specifically phosphorylated by protein kinase C (PKC) in vitro, but not by protein kinase A (PKA). A VT- peptide, on the other hand, was not a substrate for either enzyme. Phosphorylation levels of in vitro synthesized FGFR-VT+ protein by PKC were twice that of FGFR-VT- protein. In a functional assay, Xenopus oocytes expressing FGFR-VT- or FGFR-VT+ protein were equally able to mobilize intracellular Ca2+ in response to basic fibroblast growth factor (bFGF). However, pretreatment with phorbol 12-myristate 13-acetate significantly reduced this mobilization in oocytes expressing FGFR-VT+ while having little effect on oocytes expressing FGFR-VT-. These findings demonstrate that alternative splicing of Val423-Thr424 generates isoforms which differ in their ability to be regulated by phosphorylation and thus represents an important mechanism for regulating FGFR activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559402     DOI: 10.1074/jbc.270.39.22758

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Efficient use of a 'dead-end' GA 5' splice site in the human fibroblast growth factor receptor genes.

Authors:  Simon Brackenridge; Andrew O M Wilkie; Gavin R Screaton
Journal:  EMBO J       Date:  2003-04-01       Impact factor: 11.598

Review 2.  Cellular signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) in male reproduction.

Authors:  Leanne M Cotton; Moira K O'Bryan; Barry T Hinton
Journal:  Endocr Rev       Date:  2008-01-23       Impact factor: 19.871

3.  FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors.

Authors:  S H Ong; G R Guy; Y R Hadari; S Laks; N Gotoh; J Schlessinger; I Lax
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

4.  Modulation of protein phosphorylation by Mr 25,000 protein partially overlapping phosvitin and lipovitellin 2 in Xenopus laevis vitellogenin B1 protein.

Authors:  Isamu Sugimoto; Eikichi Hashimoto
Journal:  Protein J       Date:  2006-02       Impact factor: 2.371

5.  Opposite phenotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for Fgfr1 in anteroposterior patterning of mouse embryos.

Authors:  J Partanen; L Schwartz; J Rossant
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

6.  Zebrafish fgfr1 is a member of the fgf8 synexpression group and is required for fgf8 signalling at the midbrain-hindbrain boundary.

Authors:  Steffen Scholpp; Casper Groth; Claudia Lohs; Michael Lardelli; Michael Brand
Journal:  Dev Genes Evol       Date:  2004-05-25       Impact factor: 0.900

7.  Phosphorylation of Threonine 794 on Tie1 by Rac1/PAK1 Reveals a Novel Angiogenesis Regulatory Pathway.

Authors:  Jessica L Reinardy; Daniel M Corey; Christelle Golzio; Sarah B Mueller; Nicholas Katsanis; Christopher D Kontos
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.